Senescent cells perturb intestinal stem cell differentiation through Ptk7 induced noncanonical Wnt and YAP signaling

Jina Yun
Genentech Inc.
January 1, 2023
Nat Commun
https://pubmed.ncbi.nlm.nih.gov/36631445

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/36631445

Research summary

This study investigates how senescent cells influence intestinal stem cell (ISC) differentiation. The researchers identify the secreted N-terminal domain of Ptk7 as a key component of the senescence-associated secretory phenotype (SASP) that activates noncanonical Wnt/Ca²⁺ signaling through FZD7 in ISCs. This activation leads to nuclear translocation of YAP and expression of YAP/TEAD target genes, impairing ISC differentiation and crypt formation.

Key outcome of the study

Secreted Ptk7 from senescent cells activates noncanonical Wnt/Ca²⁺ signaling via FZD7, leading to YAP activation and impaired ISC differentiation. Conditional deletion of Ptk7 in mice rescues these effects, highlighting its role in age-related intestinal dysfunction.

Model

Ptk7(fl/fl) conditional Knockout mouse model developed by genOway, allowing for tissue-specific deletion of Ptk7 to study its role in ISC function and differentiation.

TARGET:
Ptk7
Synonyms:
Protein tyrosine kinase 7, CCK4

Keywords

Aging, Intestinal stem cells, Senescence, Wnt signaling, YAP/TEAD pathway

Technical specifications

Conditional Knockout model, LoxP-flanked Ptk7 alleles, Tissue-specific Cre recombinase, Organoid culture, ISC differentiation assays

Related products

Catalogue product

KO repository

>2000 conditional Knockout mouse models for target discovery and  confirmation, in vivo compound specificity, MOA, and clinical studies

Customized product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe